Publications by authors named "Allen Ebens"

Claim this Profile
C
Cathepsin B Nuclear Flux in a DNA-Guided "Antinuclear Missile" Cancer Therapy.
Fei Cao, Caroline Tang, Xiaoyong Chen, Zewei Tu, Ying Jin, Allen Ebens

ACS Cent Sci· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peptide nucleic acid-dependent artifact can lead to false-positive triplex gene editing signals.
Pui Yan Ho, Zhen Zhang, Mark E Hayes, Andrew Curd, Carla Dib, Allen Ebens

Proc Natl Acad Sci U S A· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of Pan-Pim Kinase Activity and Oral Bioavailability Leading to Diaminopyrazole (GDC-0339) for the Treatment of Multiple Myeloma.
Xiaojing Wang, Wesley Blackaby, Vivienne Allen, Grace Ka Yan Chan, Jae H Chang, Allen J Ebens

J Med Chem· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade.
Jing Zheng, Yonggang Sha, Logan Roof, Oded Foreman, John Lazarchick, Allen Ebens

Cancer Lett· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 5-Azaindazole (GNE-955) as a Potent Pan-Pim Inhibitor with Optimized Bioavailability.
Xiaojing Wang, Aleksandr Kolesnikov, Suzanne Tay, Grace Chan, Qi Chao, Allen J Ebens

J Med Chem· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 3,5-substituted 6-azaindazoles as potent pan-Pim inhibitors.
Huiyong Hu, Xiaojing Wang, Grace Ka Yan Chan, Jae H Chang, Steven Do, Allen Ebens

Bioorg Med Chem Lett· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies.
Liping L Sun, Diego Ellerman, Mary Mathieu, Maria Hristopoulos, Xiaocheng Chen, Allen J Ebens

Sci Transl Med· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells.
Teemu T Junttila, Ji Li, Jennifer Johnston, Maria Hristopoulos, Robyn Clark, Allen Ebens

Cancer Res· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Pim-1 protein kinase is an important regulator of MET receptor tyrosine kinase levels and signaling.
Bo Cen, Ying Xiong, Jin H Song, Sandeep Mahajan, Rachel DuPont, Allen Ebens

Mol Cell Biol· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma.
Dongwei Li, Kirsten Achilles Poon, Shang-Fan Yu, Randall Dere, MaryAnn Go, Allen Ebens

Mol Cancer Ther· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of novel pyrazolo[1,5-a]pyrimidines as potent pan-Pim inhibitors by structure- and property-based drug design.
Xiaojing Wang, Steven Magnuson, Rich Pastor, Eric Fan, Huiyong Hu, Allen J Ebens

Bioorg Med Chem Lett· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a robust flow cytometry-based pharmacodynamic assay to detect phospho-protein signals for phosphatidylinositol 3-kinase inhibitors in multiple myeloma.
Congfen Li, Chikara Takahashi, Liangxuan Zhang, Mahrukh Huseni, Basha Stankovich, Allen Ebens

J Transl Med· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FcRL5 as a target of antibody-drug conjugates for the treatment of multiple myeloma.
Kristi Elkins, Bing Zheng, Maryann Go, Dionysos Slaga, Changchun Du, Allen Ebens

Mol Cancer Ther· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates.
Ben-Quan Shen, Keyang Xu, Luna Liu, Helga Raab, Sunil Bhakta, Allen Ebens

Nat Biotechnol· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphoma.
Bart Burington, Peng Yue, Xiaoyan Shi, Ranjana Advani, Jeffrey T Lau, Allen Ebens

Sci Transl Med· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates.
Bing Zheng, Reina N Fuji, Kristi Elkins, Shang-Fan Yu, Franklin K Fuh, Allen Ebens

Mol Cancer Ther· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma.
David Dornan, Fiona Bennett, Yvonne Chen, Mark Dennis, Dan Eaton, Allen Ebens

Blood· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection.
Andrew G Polson, Jill Calemine-Fenaux, Pamela Chan, Wesley Chang, Erin Christensen, Allen Ebens

Cancer Res· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-CD22-MCC-DM1 and MC-MMAF conjugates: impact of assay format on pharmacokinetic parameters determination.
Jean-Philippe Stephan, Pamela Chan, Chien Lee, Christopher Nelson, James Michael Elliott, Allen Ebens

Bioconjug Chem· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-BR3 antibodies: a new class of B-cell immunotherapy combining cellular depletion and survival blockade.
Wei Yu Lin, Qian Gong, Dhaya Seshasayee, Zhonghua Lin, Qinglin Ou, Allen Ebens

Blood· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma.
Andrew G Polson, Shang-Fan Yu, Kristi Elkins, Bing Zheng, Suzanna Clark, Allen Ebens

Blood· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expression pattern of the human FcRH/IRTA receptors in normal tissue and in B-chronic lymphocytic leukemia.
Andrew G Polson, Bing Zheng, Kristi Elkins, Wesley Chang, Changchun Du, Allen Ebens

Int Immunol· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An integrative biology approach for analysis of drug action in models of human vascular inflammation.
Eric J Kunkel, Marlene Dea, Allen Ebens, Evangelos Hytopoulos, Jennifer Melrose

FASEB J· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis